Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma

Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainwright, Derek A, Lesniak, Maciej S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091585/
https://www.ncbi.nlm.nih.gov/pubmed/25057450
http://dx.doi.org/10.4161/onci.28927
_version_ 1782480784505962496
author Wainwright, Derek A
Lesniak, Maciej S
author_facet Wainwright, Derek A
Lesniak, Maciej S
author_sort Wainwright, Derek A
collection PubMed
description Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.
format Online
Article
Text
id pubmed-4091585
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40915852014-07-23 Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma Wainwright, Derek A Lesniak, Maciej S Oncoimmunology Author's View Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial. Landes Bioscience 2014-05-15 /pmc/articles/PMC4091585/ /pubmed/25057450 http://dx.doi.org/10.4161/onci.28927 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Wainwright, Derek A
Lesniak, Maciej S
Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
title Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
title_full Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
title_fullStr Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
title_full_unstemmed Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
title_short Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
title_sort ménage à trois: sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091585/
https://www.ncbi.nlm.nih.gov/pubmed/25057450
http://dx.doi.org/10.4161/onci.28927
work_keys_str_mv AT wainwrightdereka menageatroissustainedtherapeuticantitumorimmunityrequiresmultiplepartnersinmalignantglioma
AT lesniakmaciejs menageatroissustainedtherapeuticantitumorimmunityrequiresmultiplepartnersinmalignantglioma

Ejemplares similares